ARD-101 Update Call - AARDVARK THERAPEUTICS INC

Explicit Guidance:

• No formal quantitative financial guidance (revenue, EPS, capex, margins, cash flow) or share count/financial metric targets provided.
• Regulatory Path: Management intends to request an FDA meeting to align on the design of a Phase 3 study intended to support a future marketing application for ARD-101.
• Development Timeline: No specific dates provided for the Phase 3 meeting or trial initiation; stated as "hope to bring you more updates soon."

Business-Segment Outlook:

• ARD-101 (PWS Program): Plan to continue development of ARD-101 for Prader-Willi Syndrome (PWS) following the lifting of the FDA clinical hold.
• Dosing Strategy: Maximum future dose will be limited to less than 800 milligrams twice daily (BID) based on QRS widening observed at higher doses in healthy volunteers.
• Phase 3 Design: Management is open to the possibility of a randomized withdrawal study (RWD) as an approved pathway, though specific trial parameters (dose, population, size) remain pending FDA alignment.
• Combination Therapy: ARD-101 is not expected to be mutually exclusive with Viacat (approved PWS therapy) for future commercial use, though Viacat patients will likely be excluded from the upcoming Phase 3 trial to ensure clear efficacy signals.
• Pipeline: R201 program progress remains undisclosed; focus remains exclusively on the PWS indication.

Market and Competitive Outlook:

• Unmet Need: Hyperphagia remains a critical unmet need; existing approved treatments (e.g., Viacat) "take the edge off" but do not eliminate the condition, do not work for all patients (contraindications exist), and require strict food security management.
• Patient Demand: High engagement and enrollment enthusiasm reported from the PWS community and advocacy groups; no anticipated struggles with recruitment despite the presence of approved competitors.
• Competitive Landscape: Multiple companies are pursuing PWS therapies with different mechanisms; the space is viewed as growing with significant capacity for new entrants given the high unmet need.
• Target Demographic: Potential for ARD-101 to serve subpopulations unsuitable for Viacat (e.g., those with specific comorbidities or poor glycemic control) or those who did not respond to Viacat.

Macro / Industry Outlook:

• Regulatory Environment: FDA has officially lifted the clinical hold on ARD-101 following a dedicated Thorough QT (TQT) study at lower doses (200mg and 400mg BID) showing no QRS or QT prolongation.
• Safety Standards: Future trials will incorporate enhanced cardiac monitoring to address QRS widening concerns; management notes that mild, asymptomatic QRS widening at higher doses was reversible, though a safe therapeutic window has not been fully defined at lower doses yet.
• Drug-Drug Interactions (DDI): At 800mg BID, ARD-101 is a strong CYP2D6 inhibitor (linked to the prior cardiac event with pitolicin); the DDI profile at the intended lower doses (<800mg) is not yet fully characterized but is expected to be less severe.

Strategic Initiatives:

• Next Clinical Step: Immediate action is to convene an FDA meeting to define the Phase 3 protocol (dose, population, trial design) to support a marketing application.
• Data Validation: Ongoing work to finalize publication strategy for the HERO and Open-Label Extension (OLE) exploratory data.
• Protocol Adjustments: Future trials will likely limit enrollment of patients on other hyperphagia therapies (like Viacat) to isolate drug effect, though this may be relaxed post-commercialization.
• Dose Optimization: Focusing on lower doses (200mg BID) based on Phase 2 data showing efficacy with a better safety profile; no clear dose-response observed between lower and higher doses in current data.

Risks and Headwinds to Outlook:

• Clinical Hold Resolution: While lifted, the program previously faced a hold due to QRS widening at 800mg BID and a serious cardiac event attributed to a drug-drug interaction (pitolicin).
• Data Limitations: HERO trial was stopped early; results are exploratory with limited statistical power. Efficacy signals (HQCT reduction) are small and require confirmation in a full, powered Phase 3 study.
• Uncertain DDI Profile: The extent of CYP2D6 inhibition at lower, therapeutic doses remains unproven and could impact trial eligibility or future prescribing.
• Statistical Significance: Management cannot guarantee statistical significance or definitive efficacy confirmation in the next trial; current data is viewed as "directionally consistent" only.
• Trial Design Uncertainty: Final trial design, duration, and dosing regimen are subject to FDA feedback and may differ from initial expectations.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic. Management expresses "confidence in the continued development" driven by the biological plausibility (mechanism of action) and consistent directional signals (improvement on drug, loss of effect upon withdrawal).
• Strategic Shift: Pivoted from 800mg BID to lower doses after safety review; views the safety data at lower doses as "encouraging" and "supportive of promising tolerability."
• Commitment: Reiterated commitment to patient safety ("number one, two, and three") and maintaining strong relationships with the PWS community.

Miscellaneous:

• Trial Status: HERO (Phase 3) was stopped early in February 2026; Open-Label Extension was subsequently terminated.
• Key Mechanism: ARD-101 acts as an oral bitter taste receptor agonist to trigger satiety hormones (CCK, GLP-1) via the vagus nerve, bypassing the hypothalamus and minimizing CNS side effects like nausea.
• Previous Results: Phase 2 open-label trial at 200mg BID showed an approximate 9-point reduction in HQCT scores.